Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the
development of revolutionary bone graft materials and bioactive coatings
for medical applications, announces that results utilizing OsteoSponge®
bone graft for foot and ankle arthrodeses procedures has been published
in the peer-reviewed journal Orthopedics. This is the second
publication for Bacterin that highlights clinical outcomes of OsteoSponge®
for foot and ankle fusion procedures.
The article reports a prospective analysis of 25 patients who underwent
foot and ankle arthrodesis involving 45 total joints. Results indicated
that 96% of patients showed radiographic fusion at 6 and 12 months
(24/25 patients) postoperative assessment, with a 97.4% overall fusion
rate (44 out of 45 joints fused). Pain was assessed pre and
postoperatively via visual analog scale (VAS), with statistically
significant improvements at 6 and 12 months relative to preoperative
pain scores. Functional outcomes were significantly improved at 6 and 12
months compared with preoperative assessment according to American
Orthopaedic Foot and Ankle Society (AOFAS) scores.
“Bacterin has made a commitment to patients, healthcare providers, and
healthcare facilities alike to provide best-in-class products supported
by proven clinical outcomes,” said Dr. Gregory Juda, Chief Scientific
Officer for Bacterin. “We have spent a considerable amount of effort and
resources supporting the clinical efficacy of our products through
peer-reviewed publications in recent years and the results of this study
further serve as testament to our role as a leader in the orthobiologic
sector.”
The full article may be accessed using the link below or located in the
March 2014 issue of Orthopedics. http://www.healio.com/~/media/Journals/ORTHO/2014/3_March/10_3928_01477447_20140225_54/10_3928_01477447_20140225_54.pdf
About Bacterin International Holdings
Bacterin International Holdings, Inc. (NYSE MKT: BONE) develops,
manufactures and markets biologics products to domestic and
international markets. These products are used in a variety of
applications including enhancing fusion in spine surgery, relief of back
pain, promotion of bone growth in foot and ankle surgery, promotion of
cranial healing following neurosurgery and subchondral repair in knee
and other joint surgeries.
Bacterin's Medical Device division develops, employs, and licenses
coatings for various medical device applications. For further
information, please visit www.bacterin.com.
Important Cautions Regarding Forward-looking Statements
This news release contains certain disclosures that may be deemed
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995 that are subject to significant risks and
uncertainties. Forward-looking statements include statements that are
predictive in nature, that depend upon or refer to future events or
conditions, or that include words such as "continue," "efforts,"
"expects," "anticipates," "intends," "plans," "believes," "estimates,"
"projects," "forecasts," "strategy," "will," "goal," "target,"
"prospects," "potential," "optimistic," "confident," "likely,"
"probable" or similar expressions or the negative thereof. Statements of
historical fact also may be deemed to be forward-looking statements. We
caution that these statements by their nature involve risks and
uncertainties, and actual results may differ materially depending on a
variety of important factors, including, among others: the Company's
ability to meet its existing and anticipated contractual obligations,
including financial covenant and other obligations contained in the
Company’s secured lending facility; the Company’s ability to manage cash
flow and achieve profitability; the Company's ability to develop,
market, sell and distribute desirable applications, products and
services and to protect its intellectual property; the ability of the
Company's sales force to achieve expected results; the ability of the
Company's customers to pay and the timeliness of such payments; the
Company's ability to obtain financing as and when needed; changes in
consumer demands and preferences; the Company's ability to attract and
retain management and employees with appropriate skills and expertise;
the Company’s ability to successfully conclude government
investigations; the impact of changes in market, legal and regulatory
conditions and in the applicable business environment, including actions
of competitors; and other factors. Additional risk factors are listed in
the Company's Annual Report on Form 10-K and Quarterly Reports on Form
10-Q under the heading "Risk Factors." The Company undertakes no
obligation to release publicly any revisions to any forward-looking
statements to reflect events or circumstances after the date hereof or
to reflect the occurrence of unanticipated events, except as required by
law.
Copyright Business Wire 2014